GlassScriptPhysician profile
Neil Kanth Amar
NPI 1437313905
$5,969.90
in general payments reported to CMS, 2019-2025
52 companies · $852 in 2025
The $852 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $549 · 2021: $1,131 · 2022: $995 · 2023: $553 · 2024: $748 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,988 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.48 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $555.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $498.63 | 2019-2025 | Hizentra, Privigen, Haegarda |
| Glaxosmithkline, LLC. | $475.22 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Blueprint Medicines Corporation | $354.21 | 2023-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $321.19 | 2019-2025 | Dupixent |
| Genzyme Corporation | $296.52 | 2019-2025 | |
| Novo Nordisk INC | $293.48 | 2019-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $261.61 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $245.03 | 2021-2025 | |
| Octapharma USA, INC. | $221.17 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $147.27 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $144.94 | 2021-2024 | Gvoke Hypopen |
| Mylan Specialty L.P. | $144.64 | 2019-2022 | |
| Alk-Abello, INC | $144.00 | 2019-2024 | Alternaria Tenuis, Timothy, Standardized, Standardized Mite D. Farinae |
| Abbott Laboratories | $134.40 | 2019-2025 | Eterna |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Amar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.